337 related articles for article (PubMed ID: 14708469)
21. [Non-steroidal antiinflammatory drug--management of gastrointestinal complications and inhibition of COX-2].
Tada Y; Nagasawa K
Nihon Rinsho; 1999 Feb; 57(2):419-24. PubMed ID: 10078017
[TBL] [Abstract][Full Text] [Related]
22. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
Howard PA; Delafontaine P
J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
[TBL] [Abstract][Full Text] [Related]
23. Aspirin and NSAID sensitivity.
Stevenson DD
Immunol Allergy Clin North Am; 2004 Aug; 24(3):491-505, vii. PubMed ID: 15242723
[TBL] [Abstract][Full Text] [Related]
24. Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect.
Chen XH; Bai JY; Shen F; Bai AP; Guo ZR; Cheng GF
Acta Pharmacol Sin; 2004 Jul; 25(7):927-31. PubMed ID: 15210067
[TBL] [Abstract][Full Text] [Related]
25. The coxibs, selective inhibitors of cyclooxygenase-2.
Rich SA
N Engl J Med; 2001 Dec; 345(23):1709. PubMed ID: 11759657
[No Abstract] [Full Text] [Related]
26. [Current status of study on selective cyclooxygenase-2 inhibitors and evaluation of its application].
He W; Liu CF; Huang CQ
Di Yi Jun Yi Da Xue Xue Bao; 2002 Feb; 22(2):184-6. PubMed ID: 12390825
[TBL] [Abstract][Full Text] [Related]
27. Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract.
Lanas A; Panés J; Piqué JM
Curr Pharm Des; 2003; 9(27):2253-66. PubMed ID: 14529405
[TBL] [Abstract][Full Text] [Related]
28. [COX-2 inhibitor to whom?].
Martio J
Duodecim; 2000; 116(12):1265-7. PubMed ID: 11988961
[No Abstract] [Full Text] [Related]
29. Dual COX inhibition and upper gastrointestinal damage.
Skelly MM; Hawkey CJ
Curr Pharm Des; 2003; 9(27):2191-5. PubMed ID: 14529399
[TBL] [Abstract][Full Text] [Related]
30. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen.
Bjarnason I; Macpherson A; Rotman H; Schupp J; Hayllar J
Scand J Gastroenterol; 1997 Feb; 32(2):126-30. PubMed ID: 9051872
[TBL] [Abstract][Full Text] [Related]
31. Pathogenesis of NSAID-induced gastroduodenal mucosal injury.
Wallace JL
Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):691-703. PubMed ID: 11566035
[TBL] [Abstract][Full Text] [Related]
32. COX-2 specific inhibitors in NSAID-intolerant patients.
Picado P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):11-6. PubMed ID: 14552699
[TBL] [Abstract][Full Text] [Related]
33. [COX-2 specific inhibitors are similar--and different].
Aly A
Lakartidningen; 2000 Sep; 97(38):4181-2. PubMed ID: 11068393
[No Abstract] [Full Text] [Related]
34. Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration.
Salzberg-Brenhouse HC; Chen EY; Emerich DF; Baldwin S; Hogeland K; Ranelli S; Lafreniere D; Perdomo B; Novak L; Kladis T; Fu K; Basile AS; Kordower JH; Bartus RT
J Pharmacol Exp Ther; 2003 Jul; 306(1):218-28. PubMed ID: 12676885
[TBL] [Abstract][Full Text] [Related]
35. [Adverse effect-free analgesia. New COX-2 inhibitor is even more selective].
MMW Fortschr Med; 2003 May; 145(18):54. PubMed ID: 12808824
[No Abstract] [Full Text] [Related]
36. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation.
Wallace JL; Zamuner SR; McKnight W; Dicay M; Mencarelli A; del Soldato P; Fiorucci S
Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G76-81. PubMed ID: 14665439
[TBL] [Abstract][Full Text] [Related]
37. Efficacy, safety and potential clinical roles of the COX-2-specific inhibitors.
van der Bijl P; van der Bijl P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):17-22. PubMed ID: 14552700
[TBL] [Abstract][Full Text] [Related]
38. [Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
MMW Fortschr Med; 2004 Apr; 146(15):66. PubMed ID: 15373027
[No Abstract] [Full Text] [Related]
39. Cyclooxygenase 2 selective agents and upper gastrointestinal disease.
Palmer RH
JAMA; 2000 Apr; 283(15):1961-2. PubMed ID: 10789662
[No Abstract] [Full Text] [Related]
40. Cyclooxygenase 2 selective agents and upper gastrointestinal disease.
Fernandez H; Lesser GT
JAMA; 2000 Apr; 283(15):1961; author reply 1962. PubMed ID: 10789661
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
